Fri, Jan 30, 2015, 8:40 AM EST - U.S. Markets open in 50 mins.


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • frankyassissi frankyassissi Sep 12, 2013 1:37 PM Flag

    Who did SNTA screw?!

    Whoever it was has deep pockets and is #$%$. They better have something significant coming, like breast cancer or partnership, soon...all their blather about a conjugate platform is being laughed at hard and pounded by an angry animal. I'm staying long because of the miraculous breast cancer result. That would be enough to turn it around. Whenever the squeeze does happen, it will be memorable.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Adam Feurstein had some negative comments regarding SNTA....he and his cronies might be challenging the big boys. Should be quite a fight. At this point I believe it is a cat and mouse game. Like killer whales tossing around seals or cats toying with their catch...(mouse)...the big boys will swoop in and start a buying frenzy that will make the shorts' heads spin. I just hope that it's a big boy battle....the squeeze play would push us into the teens.

      Sentiment: Strong Buy

      • 1 Reply to richrd_cc
      • Nah, nothing to do with AF, don't give him credit where it isn't due. SNTA screwed over some big investors earlier this year when they hyped the new RD guy who then decided to "resign for personal reasons" just two months later. Aside from just looking plain bad, management was asked point blank whether it had anything to do with upcoming Galaxy interim results being less palatable than expected, and management stuck by the line that the RD head resigned for personal reasons - which is of course complete BS. Then the Galaxy results came in worse than the market had expected, and the company decided to push the drug not as a monotherapy but a combination therapy and decided to announce that the phase 3 would only address subjects who respond to chemo, because ganet. doesn't work in chemo non-responders. That #$%$ a lot of people off, and 2m institutional long held shares dumped out of their positions. That all said, the price currently is way too low, doesn't reflect breast, doesn't reflect the new platform, and doesn't reflect the correct probability of phase 3 success in Galaxy for what is admittedly a smaller addressable market post approval than what was expected late last year. And of course we have very good technical aspects now to the stock which point to all conditions being ripe for a squeeze, especially with the number of shares held by Kovner and Coxton and the recent trading volume of the shares. They are now on the hard to borrow list for a reason, and shorts are in trouble. What would otherwise be a multi-month move back up to 9-10 based on valuation has now been turned into a potential squeeze to 30+ in a very rapid time frame when/if it fully gets going. And THEN if the squeeze is sharp, quick and brings it to a very bloated price, then I will think about shorting, if it is all pre approval and just based on the technicals and fumes.

2.47+0.020(+0.82%)Jan 29 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
ImmunoGen, Inc.
NASDAQThu, Jan 29, 2015 4:00 PM EST
Eastman Chemical Co.
NYSEThu, Jan 29, 2015 4:04 PM EST